Month: April 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients were exposed to Mycapssa® during the OPTIMAL Phase 3 Trial, including its open label extension (OLE), for a maximum treatment duration of 3.2 years Study demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders – insulin–like growth factor 1 (IGF-1) within normal limits – maintained their long-term biochemical response at the end of the study IGF-1 levels were stably maintained within normal limits at the end of the OLE period (mean IGF-1 levels at baseline and at the end of the OLE were 0.92 and 0.84 respectively) Growth hormone (GH) levels also improved at the end of the OLE period...

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3 Illuminate results and post-hoc analyses to be presented at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting Corporate strategy to focus on accelerating the development of Axiomer® RNA base-editing technology platform across multiple therapeutic areas; Company to continue development of select Inherited Retinal Disease (IRD) programs, subject to regulatory feedback Company will implement restructuring initiatives including a 30% workforce reduction, extending cash runway into 2025 Conference call today at 8:00am...

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 – 21, 2022. About HOOKIPA HOOKIPA is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes...

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company’s website at www.axogeninc.com and clicking on the webcast link. Following the conference...

BOSTON and LAUSANNE, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator...

Figure 1 Plan view of the Twin Hills mineral resource area and mineralization domainsFigure 2 Oblique view looking northeast showing mineralization domainsFigure 3 Plan view of the main target areas showing section linesFigure 4 Bulge Section 1 looking northeast showing mineralization and drill assays (refer to Figure 3)Figure 5 Twin Hills Central Section 2 looking southeast showing mineralization and drill assays (refer to Figure 3)Figure 6 Clouds Section 3 looking southeast showing mineralization and drill assays (refer to Figure 3)Figure 7 Plan view showing material in the reporting pit shells above 0.5 g/t Au (mineral resource reporting cut-off)Figure 8 Plan view showing material in the reporting pit shells above 0.5 g/t Au (mineral resource reporting cut-off)Figure 9 Plan view showing the mineral resource...

Annual program showcases 10 companies with innovations in hardware to enable artificial intelligence, 5G and other IoT capabilities IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Industrial Internet of Things (IoT) and the Intelligent IT market, today announced that it has been named among CRN’s 2022 10 Coolest IoT Hardware Companies. Some of the other companies joining Lantronix on CRN’s 2022 list are Cisco, Dell Technologies, Intel and Qualcomm. CRN’s 2022 list of 10 Coolest IoT Hardware Companies honors organizations with innovations in hardware that enable artificial intelligence, 5G and other IoT capabilities. CRN® is a brand of The Channel Company. The full 2022 CRN IoT 50 winner list is featured online in the April issue of CRN Magazine. Compiled...

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE: FTAI) (the “Company”) today announced it will transfer its common shares listing from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market. The Company expects that its common shares will commence trading as a Nasdaq-listed security on April 26, 2022 and will continue to be listed under the ticker symbol “FTAI” after the transfer. The Company expects that its preferred shares will also transfer to Nasdaq and trade under ticker symbols FTAIP, FTAIO, and FTAIN. “Transferring to Nasdaq aligns with our growth strategy and we believe our shareholders will benefit from Nasdaq’s market maker model. We look forward to deploying Nasdaq’s proprietary investor targeting solutions, index inclusion opportunities and Nasdaq’s...

VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (TSX: EDR, NYSE: EXK) is pleased to report continued high-grade drill results from its ongoing exploration program at the Guanacevi Mine in Durango State, Mexico. The Company continues to drill the El Curso property, which covers the prolific Santa Cruz vein between Endeavour’s previously mined Porvenir Cuatro orebody and the Milache orebody currently being mined. The Company recently amended its lease agreement relating to the El Curso property with Ocampo Mining SA de CV, a subsidiary of Grupo Frisco, to include rights to an additional 145 hectares of adjacent concessions covering the area between Porvenir Cuatro and Milache that connects the currently defined resources and workings. The drill results announced...